AVALO THERAPEUTICS, INC.

Analyst Reco. Avalo Therapeutics, Inc.

Equities

AVTX

US05338F3064

Market Closed - Nasdaq Other stock markets 21:30:00 01/05/2024 BST			5-day change	1st Jan Change
16 ^USD	-6.54%		+12.68%	+75.82%

04-17	North American Morning Briefing : Stock Futures -2-	DJ
04-16	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	04-16	MT
Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target	27/06/23	MT
Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept	27/06/23	MT
RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier	10/05/23	MT
Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50	08/02/23	MT
Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating	09/11/22	MT
Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating	08/08/22	MT
RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier	05/08/22	MT
RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept	11/07/22	MT
RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating	06/05/22	MT
Jefferies Downgrades Avalo Therapeutics to Hold from Buy, Adjusts Price Target to $0.75 from $5	03/03/22	MT
RBC Cuts Price Target on Avalo Therapeutics to $4 From $5, Maintains Outperform Rating, Speculative Risk Qualifier	03/03/22	MT
Oppenheimer Adjusts Avalo Therapeutics PT to $5 From $7, Maintains Outperform Rating	10/11/21	MT
AVALO THERAPEUTICS : RBC Initiates Avalo Therapeutics With Outperform Rating, Speculative Risk Qualifier, Sets Price Target at $6	24/09/21	MT
CERECOR : Cantor Fitzgerald Initiates Coverage on Cerecor With Overweight Rating, $7 Price Target	04/06/21	MT
CERECOR : Oppenheimer Adjusts Cerecor PT to $7 From $9 on Q1 Results and Ahead of Top-Line Data, Maintains Outperform Rating	24/05/21	MT
CERECOR : Maxim Upgrades Cerecor to Buy from Hold, Sets $7 Price Target	21/04/21	MT
CERECOR : Jefferies Initiates Cerecor at Buy with $4 Price Target	20/04/21	MT
CERECOR : Oppenheimer Adjusts Cerecor PT to $9 From $10, Maintains Outperform Rating	18/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer